An evolutionary tree of more than 161 dog breeds has been mapped out by geneticists, showing which types are closely related to each other. The research will be of obvious interest to dog owners but it is hoped it will shed light on the causes of diseases that affect both dogs and humans, including epilepsy.
Promising results from a large-scale, controlled, Phase 3 clinical study of epilepsy patients being treated with cannabidiol will be presented next week at the American Academy of Neurology’s Annual Meeting in Boston on April 25. GW Pharmaceuticals’ liquid oral formulation of cannabidiol (CBD), called Epidiolex, is one of 500 compounds found in cannabis. Unlike the well-known compound, tetrahydrocannabinol (THC), CBD does not produce a “high” as the psychoactive component is absent. Results from the randomized, double-blind, placebo-controlled study found that almost 40 percent of people with Lennox-Gastaut syndrome (LGS) had at least a 50 percent reduction in drop seizures, compared to 15 percent taking a placebo. LGS is a severe form of epilepsy that often results in impaired intellectua...
Consider two children who have childhood absence epilepsy (CAE), the most common form of pediatric epilepsy. They both take the same drug—one child sees an improvement in their seizures, but the other does not. A new study in the Annals of Neurology identified the genes that may underlie this difference in treatment outcomes, suggesting there may be potential for using a precision medicine approach to help predict which drugs will be most effective to help children with CAE. The study was funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), both part of the National Institutes of Health. “A better understanding of genetic factors underlying a disease and the way t...
The first refractory epilepsy patients have been implanted with Prometra II programmable infusion pumps for a clinical trial of the dose-delivery devices, according to the product’s developers, Flowonix Medical and Cerebral Therapeutics. Dan Abrams, Cerebral Therapeutics’ CEO, said the multi-center ADDRESS trial is the first study of programmable, implantable pumps delivering medication directly to the brain — what is called intracerebroventricular delivery.
Imagine a seismograph — the instrument that measures and records earthquakes and volcanic eruptions — for your brain. Except this one has a wireless link to a device implanted in your head that stops epileptic seizures at their source, halting the sudden and violent attacks before they happen. It’s not science fiction.
Researchers suggest that Marmite may benefit brain function. Marmite is far from one of the most popular foods in the United States. In fact, many Americans are unlikely to have heard of it. A new study, however, suggests that when it comes to boosting brain function, Marmite triumphs over peanut butter.
We are often judged by the company we keep, even unfairly. For decades, that has been the fate of cannabidiol, a chemical compound that has the bad luck to occur naturally in marijuana, the world’s most controversial plant. Because cannabidiol is subject to the same tight legal restrictions on personal and scientific use as is marijuana, its potential medical benefits have been underappreciated — at least up until now.
More than 50 million people of all ages suffer from epilepsy, otherwise known as seizure disorder, the fourth most common neurological disease in the world. Patients diagnosed with epilepsy often experience recurrent seizures triggered by the firing of a large collection of neurons in the brain. This ultimately generates a high-energy wave that spreads across the surface of the brain, resulting in numerous physical effects such as erratic body shaking, unconsciousness, exhaustion, and pain.
An epilepsy patient’s emotional well-being may be negatively impacted when changes are made to their antiepileptic drug (AED) regimen. These are the findings from a study published online in the journal Epilepsy and Behavior. In order to understand how AED changes affect patient emotions, researchers asked members of an online epilepsy community to participate in an online survey which consisted of 31 questions that rated their feelings on a recent AED change. In addition to the survey results, comments from epilepsy-related online forums and social media websites where people expressed their experiences with AED changes were also analyzed (termed passive listening statements).
Prolonged epileptic seizures may cause serious problems that will continue for the rest of a patient’s life. As a result of a seizure, neural connections of the brain may be rewired in an incorrect way. This may result in seizures that are difficult to control with medication. Mechanisms underlying this phenomenon are not entirely known, which makes current therapies ineffective in some patients.
A new study published in Epilepsia found that although most newly diagnosed cases of epilepsy in older adults are treated appropriately with monotherapy, only half of those patients receive treatment within the recommended time frame, and a substantial portion were prescribed older antiepileptic drugs (AEDs) despite recommendations to use newer AEDs in this population.
We have been posting about using Zebrafish to model epilepsy treatment since 2013, and about the potential for treatments to be developed from these models. Fast forward to 2017, and we have a viable treatment in clinical trials! Via News Medical: New drug discovered in zebrafish model of pediatric epilepsy shows promising results in clinical study “Bench-to-bedside” describes research that has progressed from basic science in animal models that has led to therapies used in patients. Now, a study in the journal Brain describes what could be considered a direct “aquarium-to-bedside” approach, taking a drug discovered in a genetic zebrafish model of epilepsy and testing it, with promising results, in a small number of children with the disease. The study was supported...